Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Comparative Treatment Patterns and Outcomes of Fulvestrant Versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World ExperienceTher Clin Risk Manag 2020 Aug 01;16(2020)607-615, Y Li, Y Xie, C Gong, Y Zhao, J Zhang, S Zhang, L Wang, S Chen, X Hu, B Wang
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.